Yun-Rak Choi1,2,3, Kelsey H Collins1,2, Jin-Woo Lee3, Ho-Jung Kang3, Farshid Guilak1,2,4. 1. 1Department of Orthopaedic Surgery, Washington University in St. Louis, 1 Brookings Dr, St. Louis, MO 63130 USA. 2. 2Shriners Hospitals for Children - St. Louis, 4400 Clayton Ave, St. Louis, MO 63110 USA. 3. 3Department of Orthopaedic Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722 Republic of Korea. 4. Center of Regenerative Medicine, Campus Box 8233, McKinley Research Bldg, Room 3121, St. Louis, MO 63110 USA.
Abstract
BACKGROUND: Osteoarthritis (OA) is a highly prevalent degenerative joint disease involving joint cartilage and its surrounding tissues. OA is the leading cause of pain and disability worldwide. At present, there are no disease-modifying OA drugs, and the primary therapies include exercise and nonsteroidal anti-inflammatory drugs until total joint replacement at the end-stage of the disease. METHODS: In this review, we summarized the current state of knowledge in genetic and epigenetic associations and risk factors for OA and their potential diagnostic and therapeutic applications. RESULTS: Genome-wide association studies and analysis of epigenetic modifications (such as miRNA expression, DNA methylation and histone modifications) conducted across various populations support the notion that there is a genetic basis for certain subsets of OA pathogenesis. CONCLUSION: With recent advances in the development of genome editing technologies such as the CRISPR-Cas9 system, these genetic and epigenetic alternations in OA can be used as platforms from which potential biomarkers for the diagnosis, prognosis, drug response, and development of potential personalized therapeutic targets for OA can be approached. Furthermore, genome editing has allowed the development of "designer" cells, whereby the receptors, gene regulatory networks, or transgenes can be modified as a basis for new cell-based therapies.
BACKGROUND:Osteoarthritis (OA) is a highly prevalent degenerative joint disease involving joint cartilage and its surrounding tissues. OA is the leading cause of pain and disability worldwide. At present, there are no disease-modifying OA drugs, and the primary therapies include exercise and nonsteroidal anti-inflammatory drugs until total joint replacement at the end-stage of the disease. METHODS: In this review, we summarized the current state of knowledge in genetic and epigenetic associations and risk factors for OA and their potential diagnostic and therapeutic applications. RESULTS: Genome-wide association studies and analysis of epigenetic modifications (such as miRNA expression, DNA methylation and histone modifications) conducted across various populations support the notion that there is a genetic basis for certain subsets of OA pathogenesis. CONCLUSION: With recent advances in the development of genome editing technologies such as the CRISPR-Cas9 system, these genetic and epigenetic alternations in OA can be used as platforms from which potential biomarkers for the diagnosis, prognosis, drug response, and development of potential personalized therapeutic targets for OA can be approached. Furthermore, genome editing has allowed the development of "designer" cells, whereby the receptors, gene regulatory networks, or transgenes can be modified as a basis for new cell-based therapies.
Entities:
Keywords:
Gene editing; Genetics; Osteoarthritis; Personalized medicine
Authors: Ingrid Meulenbelt; Josine L Min; Steffan Bos; Naghmeh Riyazi; Jeanine J Houwing-Duistermaat; Henk-Jan van der Wijk; Herman M Kroon; Masahiro Nakajima; Shiro Ikegawa; André G Uitterlinden; Joyce B J van Meurs; Wendy M van der Deure; Theo J Visser; Albert B Seymour; Nico Lakenberg; Ruud van der Breggen; Dennis Kremer; Cornelia M van Duijn; Margreet Kloppenburg; John Loughlin; P Eline Slagboom Journal: Hum Mol Genet Date: 2008-03-11 Impact factor: 6.150
Authors: Lorraine Southam; Julio Rodriguez-Lopez; James M Wilkins; Manuel Pombo-Suarez; Sarah Snelling; Juan J Gomez-Reino; Kay Chapman; Antonio Gonzalez; John Loughlin Journal: Hum Mol Genet Date: 2007-07-06 Impact factor: 6.150
Authors: Martha C Castaño Betancourt; Frederic Cailotto; Hanneke J Kerkhof; Frederique M F Cornelis; Sally A Doherty; Deborah J Hart; Albert Hofman; Frank P Luyten; Rose A Maciewicz; Massimo Mangino; Sarah Metrustry; Kenneth Muir; Marjolein J Peters; Fernando Rivadeneira; Maggie Wheeler; Weiya Zhang; Nigel Arden; Tim D Spector; Andre G Uitterlinden; Michael Doherty; Rik J U Lories; Ana M Valdes; Joyce B J van Meurs Journal: Proc Natl Acad Sci U S A Date: 2012-05-07 Impact factor: 11.205
Authors: Pablo Perez-Pinera; D Dewran Kocak; Christopher M Vockley; Andrew F Adler; Ami M Kabadi; Lauren R Polstein; Pratiksha I Thakore; Katherine A Glass; David G Ousterout; Kam W Leong; Farshid Guilak; Gregory E Crawford; Timothy E Reddy; Charles A Gersbach Journal: Nat Methods Date: 2013-07-25 Impact factor: 28.547
Authors: Amber T Collins; Guoli Hu; Hunter Newman; Michael H Reinsvold; Monique R Goldsmith; John N Twomey-Kozak; Holly A Leddy; Deepika Sharma; Leyao Shen; Louis E DeFrate; Courtney M Karner Journal: Sci Rep Date: 2021-01-15 Impact factor: 4.379
Authors: Devin Drummer; Jeremy McAdam; Regina Seay; Arny Ferrando; S Louis Bridges; Jasvinder A Singh; Marcas Bamman Journal: Front Rehabil Sci Date: 2021-08-23
Authors: Alekya S Tanikella; Makenna J Hardy; Stephanie M Frahs; Aidan G Cormier; Kalin D Gibbons; Clare K Fitzpatrick; Julia Thom Oxford Journal: Int J Mol Sci Date: 2020-08-22 Impact factor: 5.923